No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null (OR, 1.0; 95% confidence interval, 0.8-1.3); recurrence ORs for individual drugs ranged from 0.3 to 3.4. The individual ORs followed the pattern expected under a null-centered Gaussian distribution. Null associations were apparent for all drugs after empirical Bayes adjustment for multiple comparisons. Together, these results provide evidence for a null association between drug-compromised CYP2D6 activity and breast cancer recurrence among tamoxifen-treated women.
Ahern
Thomas P
TP
Department of Epidemiology, Boston University School of Public Health, 715 Albany Street, T3E, Boston, MA 02118, USA. tpa@bu.edu
Pedersen
Lars
L
Cronin-Fenton
Deirdre P
DP
Sørensen
Henrik Toft
HT
Lash
Timothy L
TL
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000201:enzymology / Q000473:pathology*; D012008:Recurrence; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6
Eur J Clin Pharmacol. 2004 Jul;60(5):329-36
15168101
Acta Oncol. 2008;47(4):506-24
18465317
Br J Clin Pharmacol. 1992 Sep;34(3):262-5
1389951
Br J Cancer. 2008 Aug 19;99(4):616-21
18665165
Cancer Chemother Pharmacol. 2005 May;55(5):471-8
15685451
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Acta Oncol. 2008;47(4):497-505
18465316
Am J Public Health. 1989 Mar;79(3):340-9
2916724
Br J Clin Pharmacol. 2002 Aug;54(2):157-67
12207635
J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
14652237
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
14618296
Lancet Oncol. 2009 Aug;10(8):825-33
19647203
Acta Obstet Gynecol Scand. 2004 May;83(5):476-81
15059162
Clin Pharmacol Ther. 2006 Jul;80(1):61-74
16815318
Eur J Clin Pharmacol. 1996;51(1):73-8
8880055
Epidemiology. 1991 Jul;2(4):244-51
1912039
Biochem Pharmacol. 1997 Jan 24;53(2):171-8
9037249
Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):895-903
11008906